Answers are grounded in this paper and cite their sources.
Randomized double-blind crossover trial reveals methyldopa elevates triglycerides while oxprenolol spares them in hypertensive diabetics, suggesting differing cardiovascular risks.
1 Twelve-week courses of oxprenolol and methyldopa were administered in a randomised, double-blind cross over study to ten insulin dependent hypertensive diabetics. 2 Prior to treatment, and at the end of each period of drug administration, fasting levels of high density lipoprotein, triglycerides, free fatty acids and cholesterol were measured. 3 Neither preparation altered levels of high density lipoprotein and cholesterol, but both drugs significantly reduced the free fatty acids. 4 Whereas oxprenolol did not alter triglyceride levels, methyldopa significantly elevated triglycerides above pre-treatment values. 5 Oxprenolol does not appear to influence lipoprotein fractions affecting the relative risks of coronary heart disease, but methyldopa seems to have potentially detrimental effects of triglyceride levels.
No takes yet. Share an insight, caveat, or question.
Benfield et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: